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Abstract
Introduction: An increase in oxidative stress is strongly documented in
hypertensive patients. In blood vessels, oxidative stress increases the production
of superoxide anion (O2
•–) that reacts with nitric oxide (NO) and impairs the
ability of endothelium to relax. Many reports indicate a beneficial effect of
coenzyme Q10 (CoQ) in hypertension. Coenzyme Q10 therapy may lower O2
•–
and thus decrease the complications associated with hypertension. The aim of
our study was to evaluate the effects of CoQ supplementation on antioxidative
enzyme activities and lipid peroxidation in elderly hypertensive patients. 
Material and methods: We determined the activities of superoxide dismutase 
(SOD-1) and glutathione peroxidase (GSH-Px) and the concentration of
malondialdehyde (MDA) in erythrocytes of 27 elderly (mean age 72.5 ±6.1 year)
hypertensive patients treated with indapamide at baseline and after 12 weeks
of CoQ supplementation (60 mg twice a day) in comparison with 30 healthy
elderly volunteers (mean age 76.8 ±8.5 year).
Results: Decrease of SOD-1 (p < 0.001) and insignificant reduction of GSH-Px
activities and increase of MDA (p < 0.001) level were observed in hypertensive
patients in comparison to healthy volunteers before supplementation. Coenzyme
Q10 administration resulted in a significant increase only in SOD-1 activity 
(p < 0.001). 
Conclusions: The present study indicates that CoQ improves the most important
component of the antioxidant defence system – SOD-1, which is responsible for
O2
•– scavenging. Coenzyme Q10 may be used as an additional therapeutic agent
for prophylaxis and treatment of hypertension in elderly patients.
Key words: aging, glutathione peroxidase, hypertension, oxidative stress, superoxide
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Introduction
In 1972 Igarashi et al. [1] reported that coenzyme
Q10 (CoQ) reduced elevated blood pressure in rats
treated with desoxycorticosterone and saline.
Subsequently, CoQ supplementation has been
demonstrated to have a hypotensive effect [2-4].
A possible explanation of these findings may be the
antioxidative properties of CoQ. The pathogenesis
of primary hypertension is multifactorial. It has been
accepted that oxidative stress and augmented
production of reactive oxygen species (ROS), mainly
superoxide anion (O2
•–), may have a key role [5-7].
Overproduction of O2
•– results from increased tissue
renin-angiotensin system (RAS) activation [6-8]. The
RAS is responsible for angiotensin II (AngII)
synthesis, and additionally aldosterone potentiates
the actions of this peptide [9]. Angiotensin II
enhances the generation of O2
•– via an increase of
nicotinamide adenine dinucleotide (phosphate)
reduced oxidase (NAD(P)H-oxidase) activity in
endothelium, vascular smooth muscle and
leukocytes [5, 8, 10]. In a reaction with O2
•–,
vasodilatory nitric oxide (NO) is inactivated by
conversion to peroxynitrite [11, 12]. This powerful
oxidant reacts with polyunsaturated fatty acids and
in this way initiates lipid peroxidation [11]. 
As a result, vessel wall degradation and
endothelium damage may occur [12]. Moreover, ROS
increase the synthesis of several vasoconstrictors,
such as F2α-isoprostanes, endothelin and
thromboxane A2, and decrease synthesis of
vasodilatory prostacyclin [5]. Experimental evidence
indicates that reduction in NO availability,
endothelium cell damage and disturbances in
synthesis of several tissue hormones via impaired
endothelium-dependent vasodilation may lead to
primary hypertension development [5, 8, 13].
Coenzyme Q10 exerts some impact on the
generation and half-life of O2
•–. There are two
potential ways in which CoQ might suppress 
O2
•–  production. One possibility is that CoQ
decreases cytoplasmic NADH concentration by
enhancing electron shuttle mechanisms that
transfer electrons and H+ from cytoplasmic NADH
to the mito  chondrial respiratory chain. Another
possibility is that CoQ collects electrons in all cells’
plasma membranes which otherwise could be used
for generation of O2
•– [14]. Decreased levels of
reducing equivalents prevent NADH-oxidase from
generating O2
•– in endothelium and vascular
smooth muscle cells.
Organisms have developed several enzymatic
and non-enzymatic antioxidant mechanisms to
scavenge ROS. The major antioxidative enzymes
include superoxide dismutase (SOD-1), which
catalyzes the dismutation of O2
•– to hydrogen
peroxide (H2O2), and glutathione peroxidase 
(GSH-Px), which catalyzes the dismutation of H2O2
[15]. One of the intriguing ideas is that CoQ may
exert an influence on activities of antioxidative
enzymes and in this way reduce the level of ROS. 
Therefore the aim of the study was to investigate
the effects of CoQ supplementation on SOD-1 
and GSH-Px activities in elderly hypertensive
patients. In addition a lipid peroxidation marker,
malondialdehyde (MDA) concentration, was
determined.
Material and methods
Participants
Twenty-seven elderly (mean age 72.5 ±6.1 year)
hypertensive patients treated with indapamide at
baseline and after 12 weeks of CoQ supple  -
mentation (60 mg twice a day) in comparison with
30 healthy elderly volunteers (mean age 76.8 ±8.5
year) were included in the study. The patients were
evaluated by a standard physical examination and
routine clinical laboratory tests. Persons addicted
to alcohol and/or tobacco, and patients with
diabetes mellitus, ischaemic heart disease, a history
of stroke, renal failure or other conditions of known
free radical aetiology were excluded from the study. 
All participants provided written consent to
participate in the experiment, which was approved
by the local ethics committee of Collegium Medicum
in Bydgoszcz, Poland.
Experimental protocols
Each patient was treated with a pharmaceutical
preparation of 60 mg of CoQ twice a day for 
12 weeks. Blood samples were collected after
overnight fasting from the cubital vein into
polypropylene heparinized tubes (6 ml) a day before
supplementation, and after 12 weeks of CoQ
treatment. 
All samples were centrifuged (2500 g for 10 min).
After plasma removal, the haemolysate was
prepared by threefold freezing and thawing the
washed erythrocytes, suspended in bi-distilled
water. 
Biochemical analysis
Erythrocytic MDA, SOD-1, and GSH-Px were
assayed according to the methods of Placer et al.
[16], Misra and Fridovich [17], and Paglia and
Valentine [18], respectively. The MDA level was
expressed as the concentration of thiobarbituric
acid reactive substances, read at 532 nm. The SOD-1
activity was determined at 37°C by recording the
increase in absorbance at 480 nm following the
auto-oxidation of adrenaline, inhibited by SOD-1.
One unit (U) of this activity is defined as the
amount of enzyme inhibiting the adrenaline auto-
oxidation by 50%. The GSH-Px activity wasArch Med Sci 4, August / 2010 515
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determined at 25°C by recording the decrease in
absorbance at 340 nm following the oxidation of
NADPH in the presence of tert-butyl hydroperoxide
as a substrate. One unit (U) of this activity is
defined as the amount of the enzyme oxidizing 
1 µmol NADPH/min. The haemoglobin concen  -
tration in the haemolysate was estimated after
conversion into cyanmethaemoglobin form using
a commercial reagent (Biomed, Poland) read at 
540 nm.
Statistical analysis
All the results were expressed as mean ± SEM.
One-way analysis of variance followed by the Tukey
post hoc test was performed to determine the
statistical significance of differences. The level of
significance was set at p < 0.05.
Results
The clinical characteristics of the examined groups
are presented in Table I. The parameters of oxidative
stress in erythrocytes of elderly hypertensive subjects
differed from the results obtained for healthy elderly
volunteers: MDA level (0.288 ±0.039 µmol/g Hb and
0.223 ±0.038 µmol/g Hb, respectively) (Figure 1) was
significantly higher (p < 0.001), activity of SOD-1
(2431 ±266 U/g Hb and 2916 ±352 U/g Hb,
respectively) (Figure 2) was significantly lower 
(p < 0.001) and activity of GSH-Px (14.7 ±3.2 U/g Hb
and 16.3 ±1.6 U/g Hb, respectively) (Figure 3) was
insignificantly lower.
Twelve weeks of CoQ supplementation caused
a significant decrease (p < 0.001) in the erythrocytic
MDA level (0.255 ±0.026 µmol/g Hb) (Figure 1) and
significant increase (p < 0.001) in erythrocytic 
SOD-1 activity (2677 ±321 U/g Hb) (Figure 2) in
elderly hypertensive patients. Coenzyme Q sup  -
plementation did not influence the erythrocytic
activity of GSH-Px (16.1 ±2.3 U/g Hb) (Figure 3) in
elderly hypertensive patients.
Discussion
Many authors have observed that augmented
ROS production exceeds the capacity of the
antioxidative system in the elderly [19, 20]. Enhanced
Parameters Healthy  Elderly
elderly hypertensive
volunteers group
Number of subjects 30 27
Age [years] 76.8 ±8.5 72.5 ±6.1
Sex (number of subjects) M/F 7/23 7/20
BMI [kg/m2] 24.8 ±4.6 30.9 ±3.4
Systolic blood pressure  120.6 ±4.8 152.8 ±9.3
[mmHg]
Diastolic blood pressure  80.0 ±5.0 82.5 ±6.9
[mmHg]
Plasma total cholesterol  178.9 ±15.8 195 ±28
[mg/dl]
Plasma triglyceride [mg/dl] 135.4 ±18.4 154.5 ±11.2
Plasma glucose [mg/dl] 93.28 ±16.26 82.9 ±8.7
Serum creatinine [mg/dl] 1.0 ±0.3 0.9 ±0.13
Table I. Clinical characteristics of study subjects
BMI – body mass index, M – male, F – female
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Figure 1. Effect of coenzyme Q10 (CoQ) supple  -
mentation on the concentration of malondialdehyde
(MDA) in erythrocytes of elderly hypertensive
patients in comparison with healthy elderly
volunteers. All parameters were measured at
baseline in both groups and after 12 weeks of CoQ
administration in the hypertensive group. Each value
is mean ± SEM
*p < 0.001 hypertensive patients before supplementation vs.
healthy elderly subjects, #p < 0.001 hypertensive patients
before supplementation vs. after supple  mentation
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Figure 2. Effect of coenzyme Q10 (CoQ) supple  -
mentation on the activity of superoxide dismutase
(SOD-1) in erythrocytes of elderly hypertensive
patients in comparison with healthy elderly
volunteers. All parameters were measured at
baseline in both groups and after 12 weeks of CoQ
administration in the hypertensive group. Each value
is mean ± SEM
*p < 0.001 hypertensive patients before supplementation vs.
healthy elderly subjects, #p < 0.001 hypertensive patients
before supplementation vs. after supple  mentation
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levels of ROS by-products, such as MDA, carbonyl
groups, advanced end products of glycation and
damaged 8-oxo-2’-deoxyguanosine, were found in
elderly people [21]. Hypertension is an age-
dependent disorder and oxidative stress may be
involved in the development of this disease. In our
study erythrocyte MDA level was significantly higher
in the essential hypertensive patients as compared
to the control group before treatment with CoQ.
Significantly higher MDA concentrations in
erythrocytes and plasma of hypertensive patients
have been observed in many studies [22-26]. Uddin
et al. [27] noticed a 2.6-fold higher level of MDA in
the aorta of hypertensive mice than that of
normotensive ones. These findings suggest that
increased lipid peroxidation may be associated with
elevated blood pressure. Additionally, increased
concentration of MDA may contribute to the
development of hypertension complications [22, 28]. 
Decreased activities of the antioxidative enzymes
SOD-1 and GSH-Px in hypertensive patients before
treatment were found in the present study but only
SOD-1 activity was diminished significantly. In our
previous study a significant age effect on decreasing
activity of GSH-Px was found [29]. As opposed to the
present results, Se-dependent GSH-Px activity was
reported to be unchanged or increased in several
publications [27, 30, 31]. Uddin et al. [27] observed
unchanged GSH-Px activity in hypertensive mouse
aorta. Patients with essential hypertension exhibited
increased GSH-Px activity compared to normotensive
persons in the study of Simic et al. [31]. 
Lowered SOD-1 activity in erythrocytes of
patients with essential hypertension was reported
by Baykal et al. [23], Kumar and Das [24] and
Donmez  et al. [32]. A possible explanation of
decreased SOD-1 activity in elderly people could be
aZ n 2+ ion deficiency, which may be connected with
poor diet of elderly people [30]. According to some
authors the reason for diminished activity of SOD-1
may be the oxidative modifications of enzymatic
proteins. Researchers emphasize that protein
damage induced by ROS may be related to
increasing age [33, 34]. 
Kontush et al. [35] reported a significantly lower
level of CoQ in blood of hypertensive patients. The
studies by Sohal et al. [36] indicate that sup  -
plementation of CoQ elevates the endogenous
content of this compound. Generally, the admini  -
stration of CoQ directly improved the efficiency of
antioxidative defence in the present study.
A particularly noteworthy result is a significant rise
of SOD-1 activity after CoQ supplementation. Three
isoforms of SODs exist, but SOD-1 is the major
vascular isoform and is important in scavenging of
O2
•– and enhancing availability of endothelial NO [37].
The reaction between O2
•– and NO occurs 6 times
faster than the removal of O2
•– by SOD-1. So,
increased SOD-1 activity via CoQ supplementation
may be very important in the improvement of
endothelial function. Tiano et al. [38] reported an
improvement in endothelium-dependent vasodilation
and an increase in extracellular SOD-1 activity in the
CoQ-treated group of patients. Sena et al. [39]
reported that CoQ therapy increases Mn-SOD activity
in the pancreas of type 2 diabetic rats. The present
study showed that also the activity of GSH-Px
increased after CoQ supplementation compared to
the activity observed in the control group, but this
rise was insignificant. Contrary to these results, Sohal
et al. [36] found that intake of CoQ had no effect on 
SOD-1 and GSH-Px activities. 
Moreover, we observed that CoQ treatment
decreased erythrocytic MDA concentration, sug  -
gesting that this compound may diminish ROS
concentration. Decreased MDA levels in the plasma
after administration of CoQ were also noted by
Ankola et al. [40]. In the study by Sena et al. [39]
CoQ treatment decreased pancreatic MDA level in
diabetic rats. 
In conclusion, the results from the present study
provide evidence for an increase in MDA level and
a decrease in activities of antioxidative enzymes in
hypertensive patients before Q10 supplementation
and suggest that these changes may be associated
with the process of hypertension. The improvement
of oxidative stress parameters after CoQ sup  -
plementation confirms the antioxidative properties
of this compound. As was mentioned above, clinical
studies indicate a deficiency of CoQ concentration
in hypertensive patients. Therefore, taking into
account both hypotensive and antioxidative
properties of CoQ, we suggest the supplementation
of elderly hypertensive patients with this compound
as an alternative complementary treatment.
However, due to the small number of patients,
20
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Figure 3. Effect of coenzyme Q10 (CoQ) supple  -
mentation on the activity of glutathione peroxidase
(GSH-Px) in erythrocytes of elderly hypertensive
patients in comparison with healthy elderly
volunteers. All parameters were measured at
baseline in both groups and after 12 weeks of CoQ
administration in the hypertensive group. Each value
is mean ± SEM
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further, more comprehensive studies will be needed
to confirm the results of our study and support our
suggestions.
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